August 30, 2017

Lilly lays out faster time frame for FDA drug resubmission

Eli Lilly says it will resubmit its potential rheumatoid arthritis treatment to regulators several months faster than expected.

The drugmaker said Wednesday that it will give baricitinib back to the Food and Drug Administration for review by the end of January, and the agency will not require a new clinical study.

Lilly had said in late July that the resubmission could take at least 18 months, and regulators indicated they wanted new research. The Indianapolis drugmaker came up with a new time frame after recent talks with the federal agency.

Eli Lilly and Co. bought the potential drug from Incyte in 2009 and is leading the push to get it approved.

Rheumatoid arthritis is a chronic inflammatory disease that affects the joints and destroys soft tissue, cartilage and bone.

Citation: Lilly lays out faster time frame for FDA drug resubmission (2017, August 30) retrieved 19 July 2024 from https://medicalxpress.com/news/2017-08-lilly-faster-fda-drug-resubmission.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Lilly's rheumatoid arthritis pill rejected by regulators

0 shares

Feedback to editors

Study shows promise for a universal influenza vaccine: Scientists validate theory using 1918 flu virus

36 minutes ago

Time-lapse imaging for embryo selection in IVF does not improve the odds of live birth, large study finds

11 hours ago

Study of nurses finds modest improvements in working conditions, but big problems persist

12 hours ago

Forecasting method may help people with epilepsy predict their seizures

12 hours ago

Research points the way toward an exhaled-breath test for lung cancer

12 hours ago

Researchers draw insights from COVID-19 to inform improved health care in times of crisis

13 hours ago

Prenatal Zika infection in mothers found to have long-term immune consequences in children, even without microcephaly

13 hours ago

Brain changes linked to obesity result in low sperm count, mouse study finds

13 hours ago

Altered mealtimes linked to depression, anxiety in shift workers

13 hours ago

Meta-analysis finds 10-minute nature exposure boosts mental health

14 hours ago

Load comments (0)

Lilly lays out faster time frame for FDA drug resubmission

Study shows promise for a universal influenza vaccine: Scientists validate theory using 1918 flu virus

Time-lapse imaging for embryo selection in IVF does not improve the odds of live birth, large study finds

Study of nurses finds modest improvements in working conditions, but big problems persist

Forecasting method may help people with epilepsy predict their seizures

Research points the way toward an exhaled-breath test for lung cancer

Researchers draw insights from COVID-19 to inform improved health care in times of crisis

Prenatal Zika infection in mothers found to have long-term immune consequences in children, even without microcephaly

Brain changes linked to obesity result in low sperm count, mouse study finds

Altered mealtimes linked to depression, anxiety in shift workers

Meta-analysis finds 10-minute nature exposure boosts mental health

Lilly's rheumatoid arthritis pill rejected by regulators

US approves Sanofi, Regeneron arthritis drug

Baricitinib associated with significant improvement in RA

British court ruling backs patent protecting Lilly's Alimta

Lilly psoriasis drug fares well in late-stage test

Drug for refractory psoriatic arthritis shows promise in clinical trial

Common blood thinner heparin shows promise as cobra bite antidote

Repurposing FDA-approved drugs may decrease fibrosis in butterfly disease

Proof-of-principle study shows protein isoform inhibitors may hold the key to making opioids safer

Clinical trial: Repurposed drug improves outcomes for patients with severe COVID-19 pneumonia

Study reveals how an anesthesia drug induces unconsciousness

New research demonstrates potential for increasing effectiveness of popular diabetes, weight-loss drugs

Phys.org

Tech Xplore

Science X

Lilly lays out faster time frame for FDA drug resubmission

Study shows promise for a universal influenza vaccine: Scientists validate theory using 1918 flu virus

Time-lapse imaging for embryo selection in IVF does not improve the odds of live birth, large study finds

Study of nurses finds modest improvements in working conditions, but big problems persist

Forecasting method may help people with epilepsy predict their seizures

Research points the way toward an exhaled-breath test for lung cancer

Researchers draw insights from COVID-19 to inform improved health care in times of crisis

Prenatal Zika infection in mothers found to have long-term immune consequences in children, even without microcephaly

Brain changes linked to obesity result in low sperm count, mouse study finds

Altered mealtimes linked to depression, anxiety in shift workers

Meta-analysis finds 10-minute nature exposure boosts mental health

Related Stories

Lilly's rheumatoid arthritis pill rejected by regulators

US approves Sanofi, Regeneron arthritis drug

Baricitinib associated with significant improvement in RA

British court ruling backs patent protecting Lilly's Alimta

Lilly psoriasis drug fares well in late-stage test

Drug for refractory psoriatic arthritis shows promise in clinical trial

Recommended for you

Common blood thinner heparin shows promise as cobra bite antidote

Repurposing FDA-approved drugs may decrease fibrosis in butterfly disease

Proof-of-principle study shows protein isoform inhibitors may hold the key to making opioids safer

Clinical trial: Repurposed drug improves outcomes for patients with severe COVID-19 pneumonia

Study reveals how an anesthesia drug induces unconsciousness

New research demonstrates potential for increasing effectiveness of popular diabetes, weight-loss drugs

Newsletter sign up

Donate and enjoy an ad-free experience